Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
2.
Clin Exp Med ; 13(3): 177-86, 2013 Aug.
Article in English | MEDLINE | ID: mdl-22736247

ABSTRACT

To compare the tuberculin skin test (TST) and QuantiFERON-TB Gold In-Tube test (QFG) for the detection of latent tuberculosis infection among patients with immune-mediated inflammatory diseases before antitumor necrosis factor-α therapy. A prospective study including 153 consecutive patients with rheumatoid arthritis (n = 53), psoriasis (n = 45), inflammatory bowel disease (n = 25), and spondyloarthropathy (n = 22) were included. QFG and TST were performed simultaneously. TST was positive in 43/153 (28.1 %) patients. QFG (cutoff ≥ 0.35 IU/ml) was positive in 15/153 (9.8 %) patients, and indeterminate in one (0.7 %). QFG (cutoff ≥ 0.10 IU/ml) was positive in 25/153 (16.3 %). 59.5 % of the patients were on immunosuppressive therapy at the time of testing. There was a significant difference in the rate of positive QFG between patients with and without immunosuppressive therapy after adjustment for age and gender (cutoff ≥ 0.35 IU/ml, 4.6 vs. 17.4 %; adjusted odds ratio [AOR], 0.2; 95 % confidence interval [CI], 0.06-0.8; p = 0.03 and cutoff ≥ 0.10 IU/ml, 11.2 vs. 24.2 %; AOR, 0.3; 95 % CI, 0.1-0.93; p = 0.04). Agreement between TST and QFG was 'fair' (κ = 0.354 and κ = 0.365, for cutoffs ≥ 0.35 and ≥0.10 IU/ml, respectively). Among patients without immunosuppressive therapy, the concordance between TST and QFG was 'moderate-substantial' (κ = 0.593 and κ = 0.690, for cutoffs ≥ 0.35 IU/ml and ≥0.10 IU/ml, respectively). By contrast, among patients on immunosuppressive therapy the concordance was 'poor' (κ = 0.085; κ = 0.041, respectively). Immunosuppressive therapy affects negatively QFG performance. In patients with immune-mediated inflammatory diseases, QFG may have a limited role for screening of latent tuberculosis infection.


Subject(s)
Immune System Diseases/drug therapy , Immunosuppressive Agents/therapeutic use , Interferon-gamma Release Tests/methods , Latent Tuberculosis/diagnosis , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Prospective Studies , Sensitivity and Specificity , Tuberculin Test/methods , Tumor Necrosis Factor-alpha/therapeutic use , Young Adult
5.
Pediatr Dermatol ; 24(4): 394-6, 2007.
Article in English | MEDLINE | ID: mdl-17845164

ABSTRACT

The urea cycle is the major metabolic pathway for excretion of waste nitrogen. Ornithine transcarbamylase deficiency is the most frequent urea cycle disorder. It is a hereditary-X-linked disease with over 150 mutations described. Ornithine transcarbamylase deficiency causes vomiting, lethargy, hyperventilation, and even death, mainly in the neonatal period. Ammonia, an extremely toxic molecule for the organism, is generated during protein catabolism and is accumulated in patients with this deficiency. Part of the treatment consists of a low-protein diet, to avoid hyperammonemia episodes, which can even have a fatal outcome. Patients can become deficient in several amino acids, either through the low-protein diet or directly through the primary enzyme deficiency; this in turn can cause an acrodermatitis enteropathica-like dermatosis.


Subject(s)
Acrodermatitis/etiology , Acrodermatitis/pathology , Ornithine Carbamoyltransferase Deficiency Disease/complications , Humans , Infant , Male
7.
J Nephrol ; 18(3): 318-22, 2005.
Article in English | MEDLINE | ID: mdl-16013022

ABSTRACT

We describe the association of crescentic membranoproliferative glomerulonephritis and hypocomplementemic urticarial vasculitis syndrome. A 39-year-old woman presented edema and proteinuria and later a non-pruritic urticarial rash. Laboratory results showed nephrotic syndrome, hypocomplementemia and positive anti-C1q antibodies. Skin biopsy disclosed leukocytoclastic vasculitis. Acute renal failure developed. Renal biopsy revealed crescentic membranoproliferative glomerulonephritis. She was treated with corticosteroids and cyclosphosphamide with improvement of the renal function and partial remission of the nephrotic syndrome. Afterwards the nephrotic syndrome relapsed, mycophenolate mofetil in monotherapy was administered with reduction in proteinuria. As far as we know only 3 cases, 2 in children and one in an adult, of crescentic glomerulonephritis and hypocomplementemic urticarial vasculitis syndrome have been reported. In our patient renal manifestations preceded urticarial lesions. We provide information on the evolution during a 42-month follow-up.


Subject(s)
Acute Kidney Injury/etiology , Complement System Proteins/deficiency , Glomerulonephritis, Membranoproliferative/complications , Urticaria/complications , Vasculitis/complications , Acute Kidney Injury/drug therapy , Acute Kidney Injury/pathology , Adult , Biopsy , Cyclophosphamide/therapeutic use , Disease Progression , Drug Therapy, Combination , Female , Follow-Up Studies , Glomerulonephritis, Membranoproliferative/drug therapy , Glomerulonephritis, Membranoproliferative/pathology , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Kidney Glomerulus/pathology , Urticaria/blood , Urticaria/pathology , Vasculitis/blood , Vasculitis/pathology
11.
Ann Pharmacother ; 38(2): 261-4, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14742763

ABSTRACT

OBJECTIVE: To report a probable case of Henoch-Schönlein purpura associated with acenocoumarol therapy. CASE SUMMARY: A 76-year-old white woman was prescribed acenocoumarol for chronic atrial fibrillation. Two months after starting therapy, the patient came to our hospital's emergency department because of abdominal pain associated with vomiting. Physical examination revealed multiple round, confluent, purpuric lesions with some vesicles and an area of residual pigmentation. Lesions were present predominantly on the legs and gluteus, and also on the abdomen and arms. Skin biopsy of the lesions was compatible with leukocytoclastic vasculitis with deposition of immunoglobulin A. An upper intestinal endoscopy was done and identified purpuric mucosal lesions in the fundus, body, and antrum of the stomach and the duodenal bulb. Renal function was not affected, although proteinuria (1.26 g/day) was found and microscopic hematuria was observed. DISCUSSION: The most likely cause of the Henoch-Schönlein purpura in this case was considered to be acenocoumarol because of the close temporal relationship between exposure to the drug and onset of symptoms, as well as the rapid resolution of the symptoms and signs after acenocoumarol was discontinued. The oral anticoagulant was the only identifiable precipitant that the patient encountered before the Henoch-Schönlein purpura developed. An objective causality assessment revealed that the adverse drug event was probable. CONCLUSIONS: This case report illustrates a probable association between Henoch-Schönlein purpura and acenocoumarol. As of December 2003, this reaction had not been previously reported. Clinicians should be aware of this potential adverse effect of a widely used drug.


Subject(s)
Acenocoumarol/adverse effects , Anticoagulants/adverse effects , IgA Vasculitis/chemically induced , Aged , Female , Humans
12.
Ann Pharmacother ; 37(9): 1241-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12921507

ABSTRACT

OBJECTIVE: To report a case of photo-induced Stevens-Johnson Syndrome (SJS) due to sulfasalazine therapy. CASE SUMMARY: Photo-induced SJS associated with sulfasalazine therapy occurred in a 34-year-old white man diagnosed as having seronegative symmetrical polyarthritis with no predisposing factors. According to his medical record, the patient had received methotrexate, levofolinate calcium, deflazacort, and diclofenac sodium as needed. Two months prior to admission, methotrexate and diclofenac sodium were suspended and treatment with sulfasalazine was started. The patient presented to our emergency department because of severe erythema confined to sun-exposed areas; annular lesions on the extremities and the mucosa were affected. Nikolsky's sign was present. A skin biopsy was compatible with SJS, and the clinical diagnosis was SJS induced by sulfasalazine. Administration of sulfasalazine was suspended, which resulted in an improvement in the skin lesions and general state of health. The patient was discharged without further symptoms. DISCUSSION: The observed reaction to sulfasalazine was considered phototoxic, as lesions appeared like a burn rash reaction in sun-exposed areas when sulfasalazine treatment was started and the reaction progressed to SJS. It seems that there was a correlation between the time course of the reaction and the administration of sulfasalazine. An objective causality assessment revealed that the adverse effect was possible. CONCLUSIONS: To our knowledge, this is the first report of photo-induced SJS due to sulfasalazine therapy. Clinicians should be aware of this infrequent but severe reaction. If clinical evaluation leads to the suspicion of SJS, sulfasalazine should be discontinued immediately.


Subject(s)
Antirheumatic Agents/adverse effects , Stevens-Johnson Syndrome/etiology , Sulfasalazine/adverse effects , Sunlight/adverse effects , Adult , Antirheumatic Agents/therapeutic use , Arthritis/drug therapy , Humans , Male , Stevens-Johnson Syndrome/chemically induced , Sulfasalazine/therapeutic use
13.
Arch Intern Med ; 162(4): 474-6, 2002 Feb 25.
Article in English | MEDLINE | ID: mdl-11863483

ABSTRACT

Disulfiram is widely used in the treatment of chronic alcoholism. Adverse drug reactions with fatal outcome following disulfiram therapy are infrequent, and hepatic failure accounts for most of them. Since disulfiram is a cytochrome P450 (CYP450) enzyme system inhibitor, numerous interactions with several drugs metabolized in the liver have been reported. Like disulfiram, clarithromycin inhibits a CYP450 isoenzyme, but, despite its widespread use for the treatment of respiratory tract infections, no interactions with disulfiram have been described as yet. We report a case of fatal toxic epidermal necrolysis (Lyell disease) and fulminant hepatitis shortly after starting treatment with clarithromycin in a patient who was receiving disulfiram. This is the first case of such a severe dermatosis in a patient receiving either disulfiram or clarithromycin therapy. The temporal relationship between drug administration and clinical symptoms in this case suggests a probable interaction between the 2 drugs.


Subject(s)
Alcohol Deterrents/adverse effects , Alcoholism/drug therapy , Anti-Bacterial Agents/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Clarithromycin/adverse effects , Disulfiram/adverse effects , Enzyme Inhibitors/adverse effects , Stevens-Johnson Syndrome/etiology , Alcohol Deterrents/pharmacokinetics , Alcoholism/metabolism , Anti-Bacterial Agents/pharmacokinetics , Clarithromycin/pharmacokinetics , Cytochrome P-450 Enzyme Inhibitors , Disulfiram/pharmacokinetics , Drug Interactions , Enzyme Inhibitors/pharmacokinetics , Fatal Outcome , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...